2017

• Few people actually benefit from ‘breakthrough’ cancer immunotherapy. STAT
• PSA screening is still a bad deal.  STAT

2016

• Non financial conflict of interest: SHOW ME THE DATA! A response to NEJM

• NEJM foolish stance on data sharing

• The Statin Debate: Do we have enough evidence to recommend statins as primary prevention? No

• The Case for Rationing Cancer Drugs (STAT)

• Let NPs practice independently (STAT)

• Why a Cancer Moonshot is Unlikely to Give us a Cure.  (Washington Post)

• Don't believe what you read about Medical Errors (STAT)

2015

• Preventing cancer is biologically challenging:  Why use of surrogates and patent incentives won’t improve early cancer or chemoprevention drug development (see Below)
• Five Years of Cancer Drug Approvals: Most Cost too Much and Give us Too Little. (RAPS invited rebuttal)
• Why Are Most Cancer Drugs So Expensive. (Guest of Allen Frances at the Huffington Post)
• Perspective on the Selective reporting of primary, secondary endpoints common in randomized oncology trials. (HemOnc Today)
• The Folly of Big Science Prizes.  (The New York Times)
• The FDA generally errs on the side of approving drugs:  Why the analysis by Montazerhodjat and Lo gets it wrong.
• When Doctors Rely on Promise Instead of Proof.  (Baltimore Sun)
• Why Lisa Rosenbaum Gets Conflict of Interest Policies Wrong (Lown Institute)

2014

• Let's Take a Close Look at PARADIGM-HF (CardioExchange)
• And, the redacted discussion (CardioExchange)

2013

• President Bush's Cardiac Stent (Washington Post)
• How Should We Weight Conflicting Advice About our Health (Footnote1.com)

2012

• Clinical Researchers Meet the Physician Scientists (Kevin MD)
• Work Hour Reform is a Moral Imperative (Kevin MD)